Comparision of Analgesic Efficacy of Tramadol Infusion Versus Tramadol Plus Ondansetron Infusion In Medical Intensive Care Unit

Surya Prakash Yarramalle, Kartik Munta, S. Manimala Rao, Pradeep Marur Venkategowda, Sagar Sunka, Sai Kiran Dudam

Department of Critical Care Medicine, Yashoda Multi-Speciality Hospital, Hyderabad, Telanganag, Department of Critical Care Medicine, Apollo Hospital, Bengaluru, Karnataka, India

Abstract

Background: Tramadol, a preferred analgesic due to its less respiratory depression. It also has a central action that blocks the reuptake and enhances the release of serotonin at spinal antinociceptive pathways. Ondansetron, an antiemetic is a serotonin receptor antagonist. Due to the contradictory actions of the two drugs, co-administration of these drugs resulted in higher usage of tramadol. All these studies were done in the postoperative period. Aim: The aim of this study is to evaluate the analgesic efficacy of tramadol infusion versus tramadol plus ondansetron infusion in Medical Intensive Care Unit (ICU) patients. Materials and Methods: After Institutional Ethical Committee approval, 50 patients who experience pain other than postoperative pain were enrolled and randomized into two groups. Both the groups initially received 50 mg of tramadol intravenously over 10 min followed by Group T+O received 10 mg/h tramadol + 0.4 mg/h ondansetron as an infusion. Group T received 10 mg/h tramadol as infusion. Hemodynamic parameters along with pain assessment using Verbal Rating Scale (VRS) were analyzed at 0, 3, 6, 12, and 24 h. Rescue analgesia was administered if VRS >4. Side effects were noted by condition scoring criteria (CSC) scale. Results: Rescue analgesia was administered at 3 h, for three patients in T+O Group and 1 patient in T Group, but this is not statistically significant (P = 0.153). No rescue analgesia was required in both the groups at any other point of time. There was fall in heart rate, systolic and diastolic blood pressures, respiratory rate at 0, 3, 6, 12, and 24 h in both the groups but not statistically significant. Grade 1 sedation of CSC scale was observed in two patients of Group T+O and one patient in Group T but not statistically significant (P = 0.153). No nausea and vomiting were seen. Conclusions: We conclude that co-administration of tramadol and ondansetron can be practiced in medical ICU patients without any higher requirement in dosage of tramadol.

Keywords: Analgesia, ondansetron, tramadol

INTRODUCTION

Tramadol is one of the commonly preferred analgesics due to its less incidence of respiratory depression.1,2 It is an opioid analgesic that not only acts as the mu opioid receptor agonist for its analgesic action but also has a central analgesic action that blocks the reuptake and enhances the release of serotonin at spinal antinociceptive pathways.3-5 Ondansetron is a serotonin 5-HT3 receptor antagonist. Its usage as an antiemetic in the postoperative period, chemotherapy drugs, radiation therapy is well established.6

Due to the contradictory actions of tramadol and ondansetron on serotonin receptors, few earlier studies stated coadministration of ondansetron along with tramadol decreased the analgesic efficacy of tramadol, and there was a higher requirement of tramadol.7,8 On the contrary, there were also studies stating that coadministration of these drugs neither increased analgesic consumption nor emesis.9,10 Neither of these studies was conducted in medical intensive care patients.

We conducted a randomized prospective study in Medical Intensive Care Unit (ICU) whether there is decreased analgesic
efficacy of tramadol when co-administered with ondansetron. We have also observed for any other side effects such as nausea, vomiting, and sedation.

**Aim of the study**
The aim is to evaluate the analgesic efficacy of tramadol infusion versus tramadol plus ondansetron infusion and any side effects.

**Materials and Methods**
After taking approval from the Institutional Ethics Committee, we conducted a randomized prospective study in our medical ICU enrolling 50 patients after obtaining an informed consent who are experiencing pain other than postoperative pain. Patients were divided into two groups 25 of each.

Group T+O received 50 mg of injection tramadol slow intravenously over 10 min followed by 10 mg/h tramadol +0.4 mg/h ondansetron as an infusion.

Group T received 50 mg of injection tramadol slow intravenously over 10 min followed by 10 mg/h tramadol as an infusion.

**Inclusion criteria**
- Age: 18–70 years.

**Exclusion criteria**
- Age <18 years
- Pregnant patients, lactating patients
- Known seizure disorder increased intracranial pressure
- Patient on antidepressants
- Patient with substance abuse
- Renal or hepatic impairment patients
- Postoperative patients
- Mechanically ventilated patients
- Known allergic to tramadol or ondansetron.

Hemodynamic parameters along with pain assessment using Verbal Rating Scale (VRS) ranging from 0 to 10 were analyzed in both the groups at 0, 3, 6, 12, and 24 h. At any time if VRS >4, rescue analgesic in the form of paracetamol 1 g intravenously was supplemented. Side effects such as nausea, vomiting, and degree of sedation were assessed by a four-point ordinal scale. Data were analyzed using SPSS 24.0 IBM Analytic software [SPSS Inc.,Chicago, Illinois, USA]. We used unpaired *t*-test to know the difference between two groups.

**Results**
Fifty patients with various organ involvements requiring analgesia were enrolled into the study [Table 2]. Both the groups were demographically comparable [Table 3].

At 3 h, 3 patients in T+O Group and 1 patient in T Group required rescue analgesia, but this is not statistically significant (*P* = 0.153) [Figure 1]. No rescue analgesia was required among the groups at any other point in time as their VRS among the groups were never >4 [Table 4 and Figure 2].

**Table 1: Scoring for nausea, vomiting, and sedation**

| Condition scoring criteria | Nausea | Vomiting | Sedation |
|----------------------------|--------|----------|----------|
| 0 - No nausea              | 1 - Mild nausea, not requesting pharmacological rescue | 0 - No vomiting | 0 - Patient fully awake |
| 1 - Nausea, requesting pharmacological rescue | 1 - Vomiting, single event | 1 - Nausea resistant to pharmacological treatment |
| 2 - Nausea resistant to pharmacological treatment | 2 - Vomiting, repeated events requesting pharmacological rescue | 3 - Vomiting resistant to pharmacological treatment |
| 3 - Nausea resistant to pharmacological treatment | 3 - Vomiting resistant to pharmacological treatment |

**Table 2: Number of patients based on disease system involved**

| Disease                  | Number of cases in percentage |
|--------------------------|-------------------------------|
| Acute pancreatitis       | 17 (34%)                      |
| Pulmonary - pneumonitis  | 12 (24%)                      |
| Polytrauma               | 9 (18%)                       |
| Carcinomas               | 12 (24%)                      |

**Table 3: Demographic profiles**

| Factor          | Group T + O | Group T | *P*  |
|-----------------|-------------|---------|------|
| Age (years) mean±SD | 44.2±9.88   | 44.72±8.97 | 0.470 |
| Sex (M:F)       | 11/14       | 15/10   | 0.257 |

**Table 4: Mean VRS variation among the groups**

| Hours | VRS mean±SD         | *P*  |
|-------|---------------------|------|
|       | T + O               | T    |
| 0     | 9.96±0.2            | 9.84±0.37 | 0.8187 |
| 3     | 2.68±1.21           | 2.4±0.81  | 0.1718 |
| 6     | 1.68±0.62           | 1.64±0.56  | 0.4071 |
| 12    | 1.16±0.62           | 1.08±0.27  | 0.2804 |
| 24    | 1.08±0.57           | 1±0.5  | 0.3004 |
| 48    | 0.96±0.61           | 0.84±0.47  | 0.2205 |

Among the groups, there was fall in heart rate, systolic blood pressures, diastolic blood pressures, respiratory rate at 0, 3, 6, 12, and 24 h but no statistical significance was seen [Tables 5 and 6].

No nausea and vomiting were observed among the groups at any period. Grade 1 sedation condition scoring criteria (CSC) was observed in 2 patients of Group T+O and 1 patient in Group T, but this is not statistically significant (*P* = 0.153).

**Discussion**
Tramadol, a synthetic 4-phenyl-piperidine analog of codeine exerts its analgesic effect by possessing moderate affinity at
Yarramalle, et al.: Comparision of tramadol versus tramadol and ondansetron infusion for analgesia

Recent studies also stated a central analgesic action of tramadol at spinal level by inhibiting serotonin and nor epinephrine reuptake and blocks nociceptive impulses.\[10\]

Tramadol is metabolized in the liver by demethylation to an active metabolite O-demethyl tramadol, mediated by an isoenzyme CYP2D6 of cytochrome P450. This active metabolite possess a higher affinity for \(\mu\) receptors.\[10\] Higher plasma levels of tramadol are seen in individuals who carry two inactive copies of CYP2D6 and are known as poor metabolizers. Intermediate metabolizers are people who carry one or more inactive copies, and ultra-rapid metabolizers are people who carry more than two active copies of CYP2D6.\[12\]

Ondansetron, a serotonin 5-HT3 receptor antagonist exerts its antiemetic property by blockage of chemoreceptor trigger zone and enteric neuron 5hydroxytryptamine-3 (5HT3) receptors. Similar receptors are present on noiceptive primary afferent fibers not only on peripheral free terminal but also centrally on the spinal terminal, and these receptors are also present on neurons of the dorsal horn.\[13,14\] According to Ye et al., ondansetron has an anti-nociceptive effect similar to local anesthetics by blocking sodium channels.\[15\] Peripheral 5HT3 receptors, by binding to the opioid receptor are responsible for this anti-nociceptive action.\[16\] Cui et al. stated that there could be the release of 5-HT in dorsal horns of the spinal cord by stimulation of periaqueductal gray matter and results in inhibition of nociception of dorsal horn neurons.\[17\] These statements prove that serotonin has a role in nociceptive pathways. Studies compared tramadol as an analgesic in the postoperative period with either oral or intravenous intermittent boluses versus infusion and concluded infusion of tramadol was efficacious than oral or intravenous intermittent boluses as an analgesic.\[18,19\]

On the postoperative period, co-administration of ondansetron with tramadol by patient-controlled analgesia resulted in the decreased analgesic effect of tramadol probably due to blocking of 5-HT3 spinal receptors.\[7\] Another study also in postoperative period by patient-controlled analgesia and stated ondansetron acutely decreases the analgesic efficacy of tramadol in humans.\[9\]

A study stated coadministration of ondansetron neither increased tramadol consumption nor frequency of postoperative nausea and vomiting in the postoperative setting. Whereas plasma concentrations of O-desmethyltramadol were significantly correlated to CYP2D6 genotype, no influence was detected for ondansetron.\[9\]

We conducted the study in medical intensive care patients experiencing pain other than postoperative pain. As we are not enrolling patients with postoperative pain in this study, we preferred lower infusion doses of tramadol and ondansetron in this study with one group receiving tramadol and ondansetron infusion and the other group receiving only

---

**Table 5: Mean Heart rate and respiratory rate variations in both groups**

| Hours | Heart rate mean±SD | P | Respiratory rate mean±SD |
|-------|--------------------|---|--------------------------|
|       | \(T + O\)          |   | \(T\)                    |
| 0     | 104.32±3.90        |   | 29.36±1.15               |
| 3     | 94.3±3.34          | 0.0743 | 25.64±1.22               |
| 6     | 88.04±2.96         | 0.1138 | 21.76±1.64               |
| 12    | 82.68±2.39         | 0.3379 | 18.52±1.12               |
| 24    | 79.56±1.26         | 0.3864 | 16.72±0.89               |
| 48    | 79.6±1.55          | 0.10179 | 16.32±0.85               |

**Table 6: Mean SBP and DBP variations in both groups**

| Hours | SBP Mean±SD | P | DBP Mean±SD |
|-------|-------------|---|-------------|
|       | \(T + O\)   |   | \(T\)       |
| 0     | 154±6.58    | 0.2883 | 89.92±3.53  |
| 3     | 125.52±4.51 | 0.3701 | 80.24±2.10  |
| 6     | 123.12±4.16 | 0.4753 | 78.48±1.55  |
| 12    | 121.52±3.01 | 0.4684 | 78±1.63     |
| 24    | 120.24±1.73 | 0.4329 | 77.76±2.25  |
| 48    | 119.84±1.72 | 0.4532 | 77.44±2.32  |

---

**Figure 1: Rescue analgesia requirement**

**Figure 2: Mean verbal rating scale variation among the group**
Ondansetron inhibits the analgesic effects of tramadol, as evidenced by the study comparing tramadol alone to tramadol and ondansetron infusion for analgesia. In Group T, mean VRS score was never >4 at any other point of evaluation, while in Group T+Z, three patients had Grade 1 sedation in the 0-time interval and came down at 3 h interval (2.68 in Group T+Z and 2.4 in Group T) and mean VRS was never >4 at any other point of evaluation. Three patients in T+Z Group and 1 patient in T Group required rescue analgesia at 3 h as their VRS score was >4. No patient had nausea or vomiting in both groups according to CSC. Three patients had Grade 1 sedation in Group T+Z and 1 patient had Grade 1 sedation in Group T which were not statistically significant (P = 0.153).

**Conclusions**

We conclude that co-administration of ondansetron with tramadol can be practiced in medical ICU patients with lesser doses without any side effects such as nausea, vomiting, and sedation. More number of studies with large study population along with the determination of plasma concentrations of O-demethyltramadol is required before a conclusion can be elucidated.

**Acknowledgments**

We are very thankful to a respiratory therapist for their help extended to this study. We gratefully acknowledge management of the hospital for their valuable support.

**Financial support and sponsorship**

Nil.

**Conflicts of interest**

There are no conflicts of interest.

**References**

1. Milne RJ, Heel RC. Ondansetron. Therapeutic use as an antiemetic. Drugs 1991;41:574-95.

2. Lee CR, McTavish D, Sorkin EM. Tramadol: A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in acute and chronic pain states. Drugs 1993;46:313-40.

3. Millan MJ. The role of descending noradrenergic and serotoninergic pathways in the modulation of nociception: Focus on receptor multiplicity. In: Dickenson AH, Melmon KL, Besson JM, editors. Handbook of Experimental Pharmacology. Vol. 130. The pharmacology of pain, 6th ed. Heidelberg Springer-Verlag; 1997. p. 385-446.

4. Vickers MD. The efficacy of tramadol hydrochloride in the treatment of postoperative pain. Rev Contemp Pharmacother 1995;6:499-506.

5. Peroutka SJ, Snyder SH. Antiemetics: Neuropeptide receptor binding predicts therapeutic actions. Lancet 1982;1:658-9.

6. Trimner MR, Reynolds DJ, Stoner NS, Moore RA, McQuay HJ. Efficacy of 5-HT3 receptor antagonists in radiotherapy-induced nausea and vomiting: A quantitative systematic review. Eur J Cancer 1998;34:1836-44.

7. Arcioni R, Della Rocca M, Romanò S, Romano R, Pietropaoli P, Gasparetto A, et al. Ondansetron inhibits the analgesic effects of tramadol: A possible 5-HT3(3) spinal receptor involvement in acute pain in humans. Anesth Analg 2002;94:1553-7.

8. Vale C, Oliveira F, Assunção J, Fontes-Ribeiro C, Pereira F. Co-administration of ondansetron decreases the analgesic efficacy of tramadol in humans. Pharmacology 2011;88:182-7.

9. Rauers NI, Stüber F, Lee EH, Musshoff F, Fimmers R, Barann M, et al. Antagonistic effects of ondansetron and tramadol? A randomized placebo and active drug controlled study. J Pain 2010;11:1274-81.

10. Dayer P, Desmeules J, Collart L. Pharmacology of tramadol. Drugs 1997;53 Suppl 2:18-24.

11. Fukuda K. Opioid analgesics. In: Miller RD, Cohen NH, Eriksson LI, et al., editors. Anesthesia. 8th ed. Philadelphia: Elsevier Saunders; 2015. p. 903-31.

12. Miettus K, Cho AK, Khalil MA, Blanco K, Sasaki JD, Rawson R, et al. Trends in tramadol: Pharmacology, metabolism, and misuse. Anesth Analg 2017;124:44-51.

13. Richardson BP, Buchheit KH. The pharmacology, distribution and function of 5-HT3 receptors. In: Osborne NN, Hamon M, editors. Neuronal Serotonin. Chichester: John Wiley and Sons; 1988. p. 465-506.

14. Kidd EJ, Laporte AM, Langlois X, Fattaccini CM, Doyen C, Lombard MC, et al. 5-HT3 receptors in the rat central nervous system are mainly located on nerve fibres and terminals. Brain Res 1993;612:289-98.

15. Ye JH, Mui WC, Ren J, Hunt TE, Wu WH, Zhuzeck VK, et al. Ondansetron exhibits the properties of a local anesthetic. Anesth Analg 1997;85:1116-21.

16. Gregory RE, Ettinger DS. 5-HT3 receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting. A comparison of their pharmacology and clinical efficacy. Drugs 1998;55:173-89.

17. Cui M, Feng Y, McDoo DJ, Willis WD. Periaqueductal gray stimulation-induced inhibition of nociceptive dorsal horn neurons in rats is associated with the release of norepinephrine, serotonin, and amino acids. J Pharmacol Exp Ther 1999;289:868-76.

18. Rao SM, Netke B, Ponavala T, Kumar S, Dharmarakshak A. Post-operative pain relief by PCA v/s oral tramadol in cardiac surgery. Ann Card Anaesth 2001;4:13-6.

19. Rüd U, Fischer MV, Mewes R, Paravicini D. Postoperative analgesia with tramadol. Continuous infusion versus repetitive bolus administration. Anaesthesist 1994;43:316-21.